Real world cost of human epidermal receptor 2-positive metastatic breast cancer patients: a longitudinal incidence-based observational costing study in the Netherlands and Belgium
作者： G.W.J. Frederix , J.L. Severens , A.M. Hövels , J.G.C. van Hasselt , M.J.J. Hooiveld
DOI: 10.1111/ECC.12266
关键词:
摘要: Currently, no country-specific metastatic breast cancer (MBC) observational costing data are available for the Netherlands and Belgium. Our aim is to describe resource use costs of human epidermal receptor 2 (HER-2)-positive MBC in Belgium, making real-world data. The eligibility period patient selection was from April 2004 2010. Inclusion retrospective collection begins at time first diagnosis HER-2-positive during ends 24 months post-index or death. We identified 88 eligible patients 44 The total medical treatment other utilisation per €48 301 €37 431 Majority related trastuzumab both countries, which 50% 56% Belgium respectively. Our study provides estimates We noticed various differences patterns between countries demonstrating caution needed when transferring cost countries.
sci-hub.se 参考文章(23)
Allison Larg, John R. Moss, Cost-of-illness studies: a guide to critical evaluation. PharmacoEconomics. ,vol. 29, pp. 653- 671 ,(2011) , 10.2165/11588380-000000000-00000
Thérèse Lebrun, Bernard Selke, Jacques Bonneterre, Caroline Bercez, Marie-Edith Bonneterre, Xavier Lenne, Cancer du sein au stade avancé : évaluation du coût de la récidive Bulletin Du Cancer. ,vol. 86, pp. 585- 590 ,(1999)
R J Thomas, M Williams, C Marshall, J Glen, M Callam, The total hospital and community UK costs of managing patients with relapsed breast cancer British Journal of Cancer. ,vol. 100, pp. 598- 600 ,(2009) , 10.1038/SJ.BJC.6604911
J. Bonastre, P. Jan, Y. Barthe, S. Koscielny, Metastatic breast cancer: We do need primary cost data The Breast. ,vol. 21, pp. 384- 388 ,(2012) , 10.1016/J.BREAST.2012.03.012
Neville Davidson, Vera Gorbounova, Johannes Isaac Raats, Dimosthenis Skarlos, Beth Newstat, Debasish Roychowdhury, Paolo Paoletti, Cristina Oliva, Stephen Rubin, Steven Stein, Charles E. Geyer, David Cameron, Michelle Casey, Michael Press, Deborah Lindquist, Tadeusz Pienkowski, C. Gilles Romieu, Stephen Chan, Agnieszka Jagiello-Gruszfeld, Bella Kaufman, John Crown, Arlene Chan, Mario Campone, Patrice Viens, A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses Breast Cancer Research and Treatment. ,vol. 112, pp. 533- 543 ,(2008) , 10.1007/S10549-007-9885-0
Michael E. Stokes, David Thompson, Eduardo L. Montoya, Milton C. Weinstein, Eric P. Winer, Craig C. Earle, Ten-Year Survival and Cost Following Breast Cancer Recurrence: Estimates from SEER-Medicare Data Value in Health. ,vol. 11, pp. 213- 220 ,(2005) , 10.1111/J.1524-4733.2007.00226.X
D. Dodwell, A. Wardley, S. Johnston, Postmenopausal advanced breast cancer: options for therapy after tamoxifen and aromatase inhibitors. The Breast. ,vol. 15, pp. 584- 594 ,(2006) , 10.1016/J.BREAST.2006.01.007
SF Hurley, RM Huggins, RD Snyder, JF Bishop, The cost of breast cancer recurrences. British Journal of Cancer. ,vol. 65, pp. 449- 455 ,(1992) , 10.1038/BJC.1992.91
V. Cocquyt, K. Moeremans, L. Annemans, P. Clarys, S. Van Belle, Long-term medical costs of postmenopausal breast cancer therapy Annals of Oncology. ,vol. 14, pp. 1057- 1063 ,(2003) , 10.1093/ANNONC/MDG280
A Drucker, C Skedgel, K Virik, D Rayson, M Sellon, T Younis, THE COST BURDEN OF TRASTUZUMAB AND BEVACIZUMAB THERAPY FOR SOLID TUMOURS IN CANADA Current Oncology. ,vol. 15, pp. 136- 142 ,(2008) , 10.3747/CO.V15I3.249